HOME   |    PDF   |   


Title

Long-term outcomes of unani and allopathic therapy in oral submucous fibrosis

 

Authors

Arpita Rai 1,*, Shama Parveen 2, Mohammad Fazil 3, Gulam Rabbani 4, Zeya Ul Haque 1, Tannu Kumari 1 & Ansul Kumar 5

 

Affiliation

1Department of Oral Medicine and Radiology, Dental Institute, Rajendra Institute of Medical Sciences (RIMS), Ranchi, Jharkhand, India; 2Department of Biological sciences, Centre for Interdisciplinary Research in Basic Sciences, Jamia Millia Islamia, New Delhi, India; 3Department of Literary and Historical Research, Ansari Health Centre, Jamia Millia Islamia, New Delhi, India; 4Community Health Centre, CHC-Karra, Khunti, Jharkhand, India; 5Departmentof Cardio Thoracic Vascular Surgery (CTVS), Rajendra Institute of Medical Sciences (RIMS), Ranchi, Jharkhand, India; *Corresponding author

 

Email

Arpita Rai - E-mail: arpita.dirims@gmail.com; Phone: +91 9871743893
Shama Parveen - E-mail: shamp25@yahoo.com; Phone: +91 9818286423
Mohammad Fazil - E-mail: fazildr@yahoo.com; Phone: +91 9818345757
Gulam Rabbani - E-mail: rabbani120186@gmail.com; Phone: +91 9931072295
Zeya Ul Haque - E-mail: zeya486@gmail.com; Phone: +91 8789474713
Tannu Kumari - E-mail: tankashra@gmail.com; Phone: +91 8126783502
Ansul Kumar - E-mail: docansul@gmail.com; Phone: +91 9650965875
 

Article Type

Research Article

 

Date

Received October 1, 2026; Revised October 31, 2026; Accepted October 31, 2026, Published October 31, 2026

 

Abstract

Oral submucous fibrosis (OSMF) is a chronic, progressive and potentially malignant disorder with limited evidence on the long-term sustainability of treatment outcomes. This prospective longitudinal study evaluated 12-month outcomes of Unani formulations versus conventional allopathic antioxidant therapy following completion of a randomized controlled trial. Participants received treatment for 12 weeks and were followed for 12 months without additional intervention, with disease status and oral health-related quality of life (OHRQoL) assessed using predefined criteria and the OPMDQoL questionnaire. Among 88 participants (45 Unani and 43 allopathy), stable disease predominated (66.7% vs. 56.5%), with no significant between-group differences (all P > 0.05), while OHRQoL improved significantly within the Unani group (P = 0.001). Thus, unani formulations and allopathic antioxidant therapy showed comparable 12-month outcomes, maintaining disease stability and improving OHRQoL.

 

Keywords

Antioxidants, long-term follow-up, oral health-related quality of life, oral submucous fibrosis (OSMF), randomized controlled trial, unani medicine

 

Citation

Rai et al. Bioinformation 22(10): 6509-6516 (2026)

 

Edited by

P Kangueane

 

ISSN

0973-2063

 

Publisher

Biomedical Informatics

 

License

This is an Open Access article which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly credited. This is distributed under the terms of the Creative Commons Attribution License.